Oncology – Urological
Single-arm Phase 1b/2 study | Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial cancer.
21 Sep, 2022 | 13:10h | UTC
RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.
19 Sep, 2022 | 12:31h | UTCIntensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
My first Tweetorial 🧵 2 year toxicity results of PACE B published here. Big thanks to the 🇬🇧🇨🇦 and🇮🇪collaborators and the 874 men with prostate cancer who made this trial possible https://t.co/mERz2ox8TM
— Alison Tree 💙🇺🇦 (@alison_tree) September 14, 2022
ASCO Rapid Recommendation | Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer.
19 Sep, 2022 | 12:31h | UTC
Cohort Study | Long-term outcomes among men undergoing active surveillance for prostate cancer.
15 Sep, 2022 | 13:11h | UTCInvited Commentary: Exploring the Long-term Outcomes of Active Surveillance Among Men With Prostate Cancer—Best for Whom? – JAMA Network Open
RCT | Rezvilutamide vs. Bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer.
11 Sep, 2022 | 22:52h | UTCCommentaries:
Treatment options for metastatic hormone-sensitive prostate cancer – The Lancet Oncology
Rezvilutamide benefits shown in metastatic hormone-sensitive prostate cancer – medwire News
Commentary on Twitter
In a preplanned interim analysis of the phase III CHART trial in pts with high-volume mHSPC, rezvilutamide +ADT improve PFS (HR 0.44, 95% CI 0.33–0·.8; P<0.0001) & OS (HR 0.58, 95% CI 0.44–0.77]; P=0.0001) compared with bicalutamide + ADT: https://t.co/42IVnDUxfH #PCSM #uroonc
— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022
RCT | Adjuvant atezolizumab fails to improve outcomes in patients with renal cell carcinoma at increased risk of recurrence following resection.
11 Sep, 2022 | 22:28h | UTCAdjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentaries:
Adjuvant atezolizumab falls short in renal cell carcinoma – Urology Times
IMmotion010 does not support adjuvant atezolizumab in intermediate-, high-risk RCC – medwire News
Commentary from the author on Twitter (thread – click for more)
Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY pic.twitter.com/klAYWAQVwV
— Sumanta Pal (@montypal) September 10, 2022
30-month follow-up analysis of a RCT | Pembrolizumab vs. placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma.
5 Sep, 2022 | 14:20h | UTCInvited Commentary: Adjuvant immunotherapy for renal cell carcinoma – The Lancet Oncology
Original Article: Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma – New England Journal of Medicine
RCT | Telaglenastat failed to improve the efficacy of Cabozantinib in patients with advanced renal cell carcinoma.
5 Sep, 2022 | 14:19h | UTCEfficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
The CANTATA randomized trial of the glutaminase inhibitor telagenastat or placebo added to cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) demonstrated no improvement in efficacy with addition of telagenastat https://t.co/r9j2wmjnlF #GUCSM pic.twitter.com/ovXXEAXqi0
— JAMA Oncology (@JAMAOnc) September 1, 2022
Phase 2 RCT | Adjuvant intravesical chemohyperthermia not better than passive chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer.
25 Aug, 2022 | 12:00h | UTC
Commentary on Twitter
No benefit of adjuvant intravesical hyperthermic chemo (CHT) for intermediate-risk non–muscle-invasive bladder cancer
🔸DFS @ 24 mo was 61% vs 60%
🔸Patients treated with CHT were less likely to complete their treatment @EUplatinum @OncoAlert @Uroweb https://t.co/q8lB2MxBFf pic.twitter.com/E8Ay5hirBb— Yüksel Ürün (@DrYukselUrun) August 22, 2022
Under a Creative Commons license
M-A | Androgen receptor signaling inhibitors in addition to Docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
24 Aug, 2022 | 13:58h | UTC
Phase 2 RCT | Biomarker-selected maintenance Poly ADP-Ribose Polymerase inhibition with Rucaparib following chemotherapy for metastatic urothelial carcinoma.
15 Aug, 2022 | 11:42h | UTC
Cohort Study | Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.
11 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
Study showed men with #T2DM on GnRH for prostate cancer had a 53% higher risk of an increase in CVD risk score than those not on GnRH, suggesting the need to control cardiovascular disease risk factors in men with T2DM receiving GnRH. #OrigInvestigation https://t.co/3cJ10PpQGN
— JAMA Network Open (@JAMANetworkOpen) August 8, 2022
Guideline | Androgen deprivation therapy: adverse events and management strategies.
3 Aug, 2022 | 14:15h | UTC
Retrospective cohort study | Sequential Intravesical Gemcitabine and Docetaxel seem effective for high-risk BCG-naïve nonmuscle-invasive bladder cancer.
2 Aug, 2022 | 11:58h | UTC
Cohort Study | Assessment of second primary cancer risk among men receiving primary radiotherapy vs. surgery for the treatment of prostate cancer.
29 Jul, 2022 | 12:23h | UTC
Commentary on Twitter
In this cohort study of patients with localized prostate cancer, radiotherapy was associated with a small increase in the risk of developing a second primary cancer. https://t.co/YsrNo3FKwM
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Cohort Study | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients.
28 Jul, 2022 | 13:13h | UTCNews Release: Hormone therapy for prostate cancer increases the risk of dying from cardiovascular disease – Taylor & Francis
Guidelines on the diagnosis and treatment of prostate cancer.
20 Jul, 2022 | 12:11h | UTCThe Swedish national guidelines on prostate cancer – Scandinavian Journal of Urology
Part 2: Recurrent, metastatic and castration resistant disease
Updates on enhanced recovery after surgery for radical cystectomy.
20 Jul, 2022 | 12:03h | UTCUpdates on enhanced recovery after surgery for radical cystectomy – Therapeutic Advances in Urology
Related:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Guidelines on germline testing for urologic tumor syndromes.
15 Jul, 2022 | 12:49h | UTCGuidelines on Germline Testing for Urologic Tumor Syndromes – European Urology Focus
How to treat renal cell carcinoma: the current treatment landscape and cardiovascular toxicities.
14 Jul, 2022 | 12:35h | UTC
Genetic testing in prostate cancer management: considerations informing primary care.
13 Jul, 2022 | 11:25h | UTC
Single-arm Study | Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation.
11 Jul, 2022 | 11:56h | UTCExtended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary: Novel Focal Therapy Yields Low Rate of Serious Prostate Cancers — Trial’s 6-month rate of 6% was superior to historical control – MedPage Today (free registration required)
Commentary on Twitter
This single-arm objective performance criteria trial indicated excellent efficacy and safety profile of the second-generation high-frequency irreversible electroporation as primary treatment for localized prostate cancer. https://t.co/FheqcxJeA5
— JAMA Surgery (@JAMASurgery) July 7, 2022
RCT | Orteronel for metastatic hormone-sensitive prostate cancer.
8 Jul, 2022 | 11:18h | UTCCommentary: Orteronel Misses Goal in Metastatic Hormone-Sensitive Prostate Cancer – HealthDay
Commentary on Twitter
⛔ SWOG-1216: Orteronel did not improve overall survival for metastatic hormone sensitive #ProstateCancer ➡️ https://t.co/aejFNEb7bM #JCO #PCSM @theNCI @SWOG @neerajaiims @shilpaonc pic.twitter.com/LP5oHQqSIg
— Journal of Clinical Oncology (@JCO_ASCO) May 6, 2022
Consensus Statements | Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in patients with prostate cancer and with respect to [177Lu] Lu-PSMA radioligand therapy.
6 Jul, 2022 | 11:39h | UTCNetwork M-A | High-dose radiotherapy or androgen deprivation therapy as treatment intensification for localized prostate cancer.
6 Jul, 2022 | 11:09h | UTCHigh-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortiumhttps://t.co/rZnBjvccNe@AmarUKishan @DrSpratticus et al. pic.twitter.com/uCrg7sRmsS
— European Urology (@EUplatinum) April 25, 2022